10-Q: BullFrog AI Faces Nasdaq Scrutiny Amidst Net Losses

BullFrog AI Holdings, Inc. reported Q3 2026 results, showing increased revenue but also significant net losses and continued concerns regarding its Nasdaq listing compliance and going concern status.

Summary

• BullFrog AI Holdings, Inc. reported its Q3 2026 financial results, highlighting a decrease in collaboration revenue for the quarter compared to the prior year but an increase for the nine-month period.
• The company continues to operate at a net loss, with a loss of $2,011,881 for the three months ended September 30, 2026, and $4,976,572 for the nine months ended September 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern, as its cash position is insufficient to fund operations for at least a year beyond the filing date.
• BullFrog AI is actively seeking additional capital through various avenues, including its At-The-Market (ATM) Sales Agreement and Equity Line of Credit (ELOC) Facility.
• The company received a notice from Nasdaq regarding its stock's closing bid price falling below $1.00, and has been granted an extension until February 8, 2027, to regain compliance, potentially through a reverse stock split.
• Despite these challenges, the company has regained compliance with Nasdaq's minimum stockholders' equity requirement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued net losses, substantial doubt about its ability to continue as a going concern, and ongoing challenges with Nasdaq minimum bid price requirements, despite some revenue growth and financing activities.

Positives

• Collaboration revenue increased to $278,963 for the nine months ended September 30, 2026, up from $116,670 in the same period of 2025, driven by a new feasibility agreement.
• The company has $5.1 million in cash and cash equivalents as of September 30, 2026, an increase from $2.2 million at December 31, 2025, bolstered by financing activities.
• Regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000.
• Secured an additional 180-day compliance period from Nasdaq to address the minimum bid price requirement, extending the deadline to February 8, 2027.

Negatives

• Net loss for the three months ended September 30, 2026, was $2,011,881, compared to $1,551,612 in the prior year period.
• Net loss for the nine months ended September 30, 2026, was $4,976,572, compared to $5,017,894 in the prior year period.
• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient cash to fund operations for the next year.
• The company's common stock closing bid price was below $1.00 for 30 consecutive business days, triggering a Nasdaq compliance issue.
• Operating expenses increased significantly, with R&D up 27% and G&A up 31% for the three-month period.
• The company has an accumulated deficit of approximately $28.3 million as of September 30, 2026.

Risks

• The company's cash and cash equivalents are not sufficient to fund its planned operations for at least a year beyond the filing date, raising substantial doubt about its ability to continue as a going concern.
• Failure to regain compliance with Nasdaq's minimum bid price requirement by February 8, 2027, could lead to the delisting of the company's securities.
• The company may be forced to delay, scale back, or eliminate research and product development programs if it cannot secure sufficient funding.
• Issuance of additional equity securities to raise capital may be significantly dilutive to current shareholders.
• The company is subject to a mandatory panel monitor for one year from April 21, 2026, regarding its stockholders' equity compliance.

Future Outlook

The company anticipates increased expenses to support its service offerings, clinical and pre-clinical research and development activities, and acquired product candidates. It plans to fund these through existing cash, feasibility agreement revenues, and ongoing sales under its ELOC Facility and ATM Agreement. Management believes additional capital will be required and is exploring various avenues, though there is no assurance of securing sufficient funds on acceptable terms.

Management Comments

• "Our objective is to utilize bfLEAP, our AI/ML platform, with a precision medicine approach toward drug development with biopharmaceutical collaborators."
• "We have had negative cash flows from operations and operated at a net loss since inception."
• "Substantial doubt exists about our ability to continue as a going concern."
• "We intend to monitor the closing bid price of its Common Stock and assess potential options to regain compliance with Nasdaqs Listing Rules, including, if necessary, effecting a reverse stock split."

Industry Context

StockSavvy.ai notes that BullFrog AI operates in the rapidly evolving AI in healthcare and drug discovery sector. While the company leverages advanced AI/ML technology (bfLEAP) and has secured key partnerships, it faces significant financial hurdles common to early-stage biotech firms, including high R&D costs and the long, uncertain path to commercialization. The company's strategy to de-risk drug development and generate revenue through collaborations is a recognized approach in the industry, but execution and funding remain critical.

Comparison to Industry Standards

• The company's net loss of $4.98 million for the first nine months of 2026 is substantial for its revenue of $279,000, indicating a high burn rate typical of early-stage drug development companies, but requiring significant future funding.
• The ongoing Nasdaq minimum bid price issue is a common challenge for micro-cap and small-cap biotech companies, often necessitating reverse stock splits or other corporate actions to maintain exchange listing.
• The company's strategy of licensing technology from institutions like Johns Hopkins University and George Washington University is standard practice in the biotech industry to access cutting-edge research and intellectual property.

Legal Proceedings

• To the best of the company's knowledge, there are no current legal proceedings that are material to its financial condition or results of operations.

Stakeholder Impact

• Shareholders may experience significant dilution if the company issues additional equity to raise capital.
• Shareholders face the risk of delisting from Nasdaq if the minimum bid price requirement is not met by February 8, 2027.
• Creditors and suppliers may face uncertainty regarding timely payments if the company cannot secure sufficient funding.
• Employees may face job security concerns if the company is forced to scale back or eliminate operations due to funding shortfalls.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by February 8, 2027, potentially through a reverse stock split.
• Continue to pursue additional capital through its ATM and ELOC facilities, and other potential financing avenues.
• Execute on its feasibility agreement with a global pharmaceutical company and explore new strategic partnerships.
• Advance its drug asset enhancement business model, potentially acquiring and developing late-stage failed drugs.

Key Dates

Recommendation

The company shows potential in its AI/ML platform and has secured some revenue-generating agreements and financing. However, the significant net losses, ongoing going concern issues, and critical Nasdaq listing challenges (minimum bid price) present substantial risks. A 'hold' recommendation reflects a cautious approach, awaiting clearer signs of financial stability and successful navigation of regulatory hurdles before considering a more positive stance.

Keywords

AI drug discovery, precision medicine, bfLEAP platform, biopharmaceutical collaborations, Nasdaq compliance, going concern, equity financing, clinical trial optimization